Author

Doug C Palmer

AstraZeneca (United States)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Adam Jacob SchoenfeldiD· 1 shared Ana Camelo Stewart· 1 shared Ben S. SiddersiD· 1 shared Francesc Muyas· 1 shared Iñigo MartincorenaiD· 1 shared Jessica Davies· 1 shared Jonathan R. DryiD· 1 shared Kathleen A. BurkeiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Adam Jacob SchoenfeldORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Pan-cancer analysis in the real-world setting uncovers immunogenomic drivers of acquired resistance post-immunotherapy

Mohamed Reda Keddar, Sebastian Carrasco Pro, Roy Rabbie, Zeynep Kalender Atak, Francesc Muyas, Ana Camelo Stewart, Scott A. Hammond, Doug C Palmer, Ross A. Stewart, Maureen Carey, Kathleen A. Burke, Ben S. Sidders, Jessica Davies, Jonathan R. Dry, Iñigo Martincorena, , Martin L. Miller

This study identifies immunogenomic drivers of acquired resistance to immunotherapy across multiple cancer types using a large-scale clinicogenomic dataset.

Journal for ImmunoTherapy of Cancer · May 1, 2026Peer-reviewedCancer Biology